Sold as Angio-Conray, Conray 400, Conray 325. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 3 applications for Iothalamate Sodium (sold as Angio-Conray, Conray 400, Conray 325), first approved Sep 30, 1963, with 1 new use approved and 0 published complete response letters.
| Sep 30, 1963 | Conray 400NDA 14295 · New formulation or manufacturer | Mallinckrodt | 24 | Discontinued |
| Sep 7, 1976 | Conray 325NDA 17685 · New formulation or manufacturer | Mallinckrodt | 15 | Discontinued |
| Apr 26, 1996 | Angio-ConrayNDA 13319 · New active ingredient | Mallinckrodt | 8 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA